Company Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases.
The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG.
The company is headquartered in Hackensack. New Jersey.
| Country | United States |
| Founded | 1993 |
| IPO Date | May 15, 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 226 |
| CEO | Dror Bashan |
Contact Details
Address: 2 University Plaza, Suite 100 Hackensack, New Jersey 07601 United States | |
| Phone | 201 696 9345 |
| Website | protalix.com |
Stock Details
| Ticker Symbol | PLX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001006281 |
| CUSIP Number | 74365A309 |
| ISIN Number | US74365A3095 |
| Employer ID | 65-0643773 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dror Bashan | President, Chief Executive Officer and Director |
| Gilad Mamlok | Senior Vice President, Chief Financial Officer Treasurer and Secretary |
| Yaron Naos B.Sc., MBA | SVice President and Chief Operating Officer |
| Yael Fellous | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2026 | 8-K | Current Report |
| May 21, 2026 | 8-K | Current Report |
| May 13, 2026 | 10-Q | Quarterly Report |
| May 13, 2026 | 8-K | Current Report |
| Apr 30, 2026 | ARS | Filing |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 30, 2026 | SCHEDULE 13G/A | Filing |
| Mar 18, 2026 | 10-K | Annual Report |
| Mar 18, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 8-K | Current Report |